Attached files
| file | filename |
|---|---|
| 10-K - ANNUAL REPORT - Organicell Regenerative Medicine, Inc. | organicell_10k-103117.htm |
| EX-31.2 - CERTIFICATION - Organicell Regenerative Medicine, Inc. | organicell_ex3102.htm |
| EX-31.1 - CERTIFICATION - Organicell Regenerative Medicine, Inc. | organicell_ex3101.htm |
| EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - Organicell Regenerative Medicine, Inc. | organicell_ex2101.htm |
| EX-10.32 - FORM OF 2018 6% CONVERTIBLE DEBENTURE - Organicell Regenerative Medicine, Inc. | organicell_ex1033.htm |
| EX-3.9 - CERTIFICATE OF WITHDRAWAL - Organicell Regenerative Medicine, Inc. | organicell_ex0309.htm |
| EX-3.8 - CERTIFICATE OF COIRRECTION - Organicell Regenerative Medicine, Inc. | organicell_ex0308.htm |
| EX-3.7 - CERTIFICATE OF AMENDMENT TO ARTICLES OF INCORPORATION - Organicell Regenerative Medicine, Inc. | organicell_ex0307.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The undersigned Manuel Iglesias, Chief Executive Officer and Ian T. Bothwell, Chief Financial Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | the Annual Report on Form 10-K of Organicell Regenerative Medicine, Inc., a Nevada corporation (the “Registrant”), for the fiscal year ended October 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. |
| Date: November 1, 2018 | /s/ MANUEL IGLESIAS |
| Manuel Iglesias | |
| Chief Executive Officer | |
| (Principal Executive Officer) | |
| Date: November 1, 2018 | /s/ IAN T. BOTHWELL |
| Ian T. Bothwell | |
| Chief Financial Officer | |
| (Principal Financial and Accounting Officer) |